
CLAIMS

1. Use of an anti-HER3 antibody-drug conjugate in the manufacture of a medicament for the treatment of EGFR-TKI-resistant non-small cell lung cancer, wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence represented by SEQ ID NO:1, CDRH2 consisting of the amino acid sequence represented by SEQ ID NO:2, and CDRH3 consisting of the amino acid sequence represented by SEQ ID NO:3, and a light chain comprising CDRL1 consisting of the amino acid sequence represented by SEQ ID NO:4, CDRL2 consisting of the amino acid sequence represented by SEQ ID NO:5, and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO:6, wherein the EGFR-TKI-resistant non-small cell lung cancer is resistant to Osimertinib, and wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A in the formula represents the connecting position to the anti-HER3 antibody,

is conjugated to the anti-HER3 antibody via a

thioether bond, wherein the anti-HER3 antibody-drug conjugate is to be administered in combination with a second drug and wherein the second drug is osimertinib.

2. The use according to claim 1, wherein the non-small cell lung cancer is EGFR T790M mutation-negative non-small cell lung cancer.

3. The use according to claim 1 or 2, wherein the non-small cell lung cancer expresses HER3.


4. The use according to any one of claims 1 to 3, wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:7, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:8.

5. The use according to any one of claims 1 to 4, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence represented by SEQ ID NO:9, and a light chain consisting ofthe amino acid sequence represented by SEQ ID NO:10.

6. The use according to claim 5, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of


the heavy chain.

7. The use according to any one of claims 1 to 6, wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein the drug-linker in the formula is conjugated to the anti-HER3 antibody via a thioether bond, and n is the average number of units of the drug-linker conjugated per antibody molecule wherein n is in the range of 2 to 8.

8. The use according to any one of claims 1 to 6, wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein the drug-linker in the formula is conjugated to the anti-HER3 antibody via a thioether bond, and n is a drug to antibody ratio wherein n is in the range of 2 to 8.

9. The use according to any one of claims 1 to 6, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 2 to 8.

10. The use according to any one of claims 1 to 7, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 3 to 8.

11. The use according to any one of claims 1 to 7, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 7 to 8.

12. The use according to any one of claims 1 to 7, wherein the average number of units of the drug-linker

conjugated per antibody molecule in the anti-HER3 antibody-drug conjugate is in the range of 7.5 to 8.